(Q37853831)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author

Jean-Philippe Bertocchio

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Frederic Jaisser

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

David G Warnock

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

16 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

1051-1060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21412221%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2011.48

25 January 2020

exact match

0 references

cites work

CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Eplerenone in patients with systolic heart failure and mild symptoms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mechanisms of action of cyclosporine.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Cyclosporin A in patients receiving renal allografts from cadaver donors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Multiple aspects of mineralocorticoid selectivity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The role of aldosterone and mineralocorticoid receptors in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Biological determinants of aldosterone-induced cardiac fibrosis in rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor activation and oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone induces superoxide generation via Rac1 activation in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Modulation of steroid hormone receptor activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Networking between systemic angiotensin II and cardiac mineralocorticoid receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor blockers and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Hyperkalemia: a threat to RAAS inhibition?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Development of a panel of monoclonal antibodies against the mineralocorticoid receptor.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone induces a vascular inflammatory phenotype in the rat heart

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Regression of existing glomerulosclerosis by inhibition of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The role of aldosterone blockade in murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Calcineurin inhibitor nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The natural history of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Suppression of plasma renin activity by cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Interaction of cyclosporine A and the renin-angiotensin system; new perspectives

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The incidence and implications of aldosterone breakthrough

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Control of aldosterone secretion: a model for convergence in cellular signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone in the development and progression of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Renal damage in primary aldosteronism: results of the PAPY Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Plasma aldosterone concentrations in chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone and ACE inhibition in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone blockade and vascular calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Safety of low-dose spironolactone administration in chronic haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Is spironolactone safe for dialysis patients?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The effect of aldosterone blockade in patients with Alport syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Clinical experience with spironolactone in pediatrics

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone in uremia - beyond blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Appropriateness of spironolactone prescribing in heart failure patients: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Aldosterone receptor blockade and the role of eplerenone: evolving perspectives

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Eplerenone in chronic renal disease: the EVALUATE trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

The frequency of hyperkalemia and its significance in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.48

7 January 2021